Non-Small-Cell Lung Carcinoma Clinical Trial
Official title:
Randomized Phase II Trial: Effect of All-trans Retinoic Acid With Chemotherapy Based in Paclitaxel and Cisplatin as First Line Treatment of Patients With Advanced Non-small Cell Lung Cancer
Purpose:
This randomized phase II trial evaluated whether the combination of cisplatin and paclitaxel
plus All-trans retinoic acid (ATRA) increases Response rate (RR) and Progression-free
survival (PFS) in patients with advanced Non-small cell lung cancer (NSCLC) with an
acceptable toxicity profile and its association with the expression of Retinoic acid
receptor beta 2 (RAR-beta2) as a response biomarker.
Patients and Methods:
Patients with stage IIIB and IV NSCLC were included to receive Paclitaxel and Cisplatin
(PC). Patients were randomized to receive ATRA 20 mg/m2/day (RA/PC) or placebo (P/PC) 1 week
prior to treatment until completing two cycles. RAR-beta2 expression was analyzed by
Immunohistochemistry (IHC) and RT-PCR in tumor and adjacent lung tissue.
Purpose:
This randomized phase II trial evaluated whether the combination of cisplatin and paclitaxel
plus All-trans retinoic acid (ATRA) increases Response rate (RR) and Progression-free
survival (PFS) in patients with advanced Non-small cell lung cancer (NSCLC) with an
acceptable toxicity profile and its association with the expression of Retinoic acid
receptor beta 2 (RAR-beta2 ) as a response biomarker.
Patients and Methods:
Patients with stage IIIB and IV NSCLC were included to receive Paclitaxel and Cisplatin
(PC). Patients were randomized to receive ATRA 20 mg/m2/day (RA/PC) or placebo (P/PC) 1 week
prior to treatment until completing two cycles. RAR-beta2 expression was analyzed by
Immunohistochemistry (IHC) and RT-PCR in tumor and adjacent lung tissue.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00985855 -
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00098085 -
Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04995523 -
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT00910676 -
Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors
|
Phase 2 | |
Withdrawn |
NCT00108186 -
Celecoxib Treatment for Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05037825 -
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
|
||
Recruiting |
NCT00379717 -
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Completed |
NCT00404924 -
ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures
|
Phase 3 | |
Completed |
NCT00102505 -
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT02905591 -
A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC
|
Phase 2 | |
Active, not recruiting |
NCT03088540 -
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 3 | |
Terminated |
NCT00271323 -
Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients
|
Phase 2 | |
Terminated |
NCT00232206 -
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00037817 -
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
|
Phase 1 | |
Completed |
NCT03444766 -
Study of Nivolumab for Advanced Cancers in India
|
Phase 4 | |
Completed |
NCT04351334 -
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
|
||
Active, not recruiting |
NCT02416739 -
Anticancer Activity of Nicotinamide on Lung Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00444015 -
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Completed |
NCT00105092 -
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
|
Phase 2 |